Browse by author
Lookup NU author(s): Professor Roderick Skinner
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019 Elsevier Ltd Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
Author(s): Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne N-X, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, am Zehnhoff-Dinnesen A, Cohn RJ, Landier W
Publication type: Review
Publication status: Published
Journal: The Lancet Oncology
Year: 2019
Volume: 20
Issue: 1
Pages: e29-e41
Online publication date: 03/01/2019
Acceptance date: 03/01/2019
ISSN (print): 1470-2045
ISSN (electronic): 1474-5488
Publisher: Lancet Publishing Group
URL: https://doi.org/10.1016/S1470-2045(18)30858-1
DOI: 10.1016/S1470-2045(18)30858-1
PubMed id: 30614474